Over the past 12 months, $GSK has been mentioned 57 times across FinTwit by three distinct voices, with the first mention appearing on 2025-07-17. The conversation has been dominated by @jacobplieth, who accounts for 54 of the 57 mentions, while @adamfeuerstein contributed 7 mentions and @nezih_gokay contributed 1 mention. The most recent discussion occurred on 2026-06-29 when @nezih_gokay included $GSK in a historical overview of long-established publicly traded companies, noting its origins tracing back to 1715 as Plough Court pharmacy in London and its evolution into a major pharmaceutical innovator in vaccines and chronic disease treatment.

@jacobplieth's coverage has focused on GSK's pharmaceutical and biotech activities, including recent corporate developments. On 2026-06-10, @jacobplieth noted $GSK's acquisition of $NUVL as part of a significant week of biotech deal activity. More recently on 2026-07-10, @jacobplieth commented on the Artemis-008 trial results, describing the trial design as having virtual irrelevance to western standard of care despite GSK issuing a press release about it.